CLINICAL TRIAL: GENTAMICIN IN DUCHENNE MD

临床试验：庆大霉素在 Duchenne MD 中的应用

• 批准号: 7718356
• 负责人: Richard J. Barohn
• 金额: $ 2.49万
• 依托单位: UNIVERSITY OF KANSAS MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-04-01 至 2009-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7718356
• 关键词: Clinical Trials; Computer Retrieval of Information on Scientific Projects Database; Defect; Duchenne muscular dystrophy; Dystrophin; Funding; Gentamicins; Goals; Grant; Institution; Muscle function; Proteins; Purpose; Research; Research Personnel; Resources; Source; United States National Institutes of Health; Week; gene correction; muscle strength

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The primary purpose of this study is to see if gentamicin given twice a week for a total of 6 months can be given safely. One of the secondary goals of the study is to determine if gentamicin can help correct the gene defect and allow the body to make enough dystrophin (a protein which is absent in DMD) to let the muscles function. The other secondary goal is to evaluate the effects of gentamicin on muscle strength.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 这项研究的主要目的是查看庆大霉素是否每周两次可以安全地给予6个月。 该研究的次要目标之一是确定庆大霉素是否可以帮助纠正基因缺陷，并使人体产生足够的肌营养不良蛋白（DMD中缺乏的蛋白质）使肌肉发挥作用。 另一个次要目标是评估庆大霉素对肌肉力量的影响。